# Thomas Han

> Thomas Han is the CEO and co-founder of Peroxitech, a University of Pennsylvania spinout developing the peptide program PIP-2. Across more than 30 years in pharmaceuticals, he moved from commercial roles at Bristol-Myers Squibb, Novartis, Merck, Biovail, and Bausch Health to company-building, deal evaluation, fundraising, and preclinical development. His career is defined by translating between scientific promise and the operational proof required to move an asset forward.

- **Role:** CEO and Co-Founder at Peroxitech Inc.
- **Organizations:** Peroxitech Inc., VIRAZE Pharmaceuticals, Exeltis Pharmaceuticals, Bausch Health, Biovail, Merck, Novartis, Bristol-Myers Squibb
- **Education:** Bachelor's degree in Philosophy, Binghamton University
- **Known for:** Built, relaunched, and grew pharmaceutical brands across more than 30 years in the industry., Managed portfolios exceeding $1 billion in annual revenue., Directed commercial diligence and deal modeling for more than ten acquisitions and licensing transactions totaling over $2.5 billion.

## Career timeline

- **1990-2000** — Worked in marketing at Bristol-Myers Squibb.
- **2000-2002** — Worked in marketing at Novartis.
- **2002-2005** — Worked in marketing at Merck.
- **2005-2008** — Held strategic marketing and business analysis roles at Biovail.
- **2008-2012** — Served in a vice president role at Bausch Health and helped expand its dermatology business.
- **2014-2015** — Served as a vice president at Exeltis Pharmaceuticals.
- **2015-2019** — Co-founded VIRAZE Pharmaceuticals and served as head of operations.
- **2017** — Co-founded Peroxitech and became its CEO.
- **2021** — Peroxitech was seeded and incubated at Xontogeny.
- **2022** — Peroxitech completed a $25 million Series A financing led by the Perceptive Xontogeny Venture Fund.
- **2023** — Shared Peroxitech's startup journey at the PCI Ventures at Pennovation Works Showcase.
- **2024** — Co-authored a peer-reviewed preclinical paper and was named as inventor on a Peroxitech international patent application.
- **2026** — Appeared as a featured company speaker at Biotech Alchemy in Philadelphia.

## Achievements

- Built, relaunched, and grew pharmaceutical brands across more than 30 years in the industry.
- Managed portfolios exceeding $1 billion in annual revenue.
- Directed commercial diligence and deal modeling for more than ten acquisitions and licensing transactions totaling over $2.5 billion.
- Helped expand Bausch Health's dermatology business from $250 million to $1 billion.
- Co-founded Peroxitech in 2017 and raised seed and Series A capital, including a $25 million Series A.
- Advanced Peroxitech's lead program through preclinical development.
- Co-authored a 2024 peer-reviewed study affiliated with Peroxitech.
- Was named inventor on Peroxitech's 2024 international patent application for compositions and methods related to its peptide work.

## Latest updates

- **2026-03** — Featured as a Peroxitech speaker in the 'Stars in the System' company session at Biotech Alchemy in Philadelphia.
- **2026-03** — European and Korean publications in the Peroxitech patent family for compositions and methods for treatment of septic shock were published.
- **2024-11** — Named as inventor on Peroxitech's international patent publication WO2024233384A2.
- **2024-04** — A Peroxitech-affiliated preclinical study co-authored by Han appeared in the American Journal of Physiology-Lung Cellular and Molecular Physiology.
- **2023-11** — Spoke about Peroxitech's startup journey at the PCI Ventures at Pennovation Works Showcase.

## Links

- Website: http://www.peroxitech.com/
- LinkedIn: https://www.linkedin.com/in/thomas-h-5875a511

---

Profile page: https://yespress.io/thomas-han
Published by YesPress — https://yespress.io
Last updated: 2026-08-26